Section Edited by Jason J. Luke, MD, FACP and Douglas G. McNeel, MD, PhD
Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged.
Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trialDirk Schadendorf, Jason John Luke, Paolo A Ascierto, Georgina V Long, Piotr Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz-Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S CarlinoSee the full list of authors
13 March 2024
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Sook Ryun Park, Yu Jung Kim, In Gyu Hwang, Woo Kyun Bae, Jae Ho Byun, Jung Sun Kim, Eun Joo Kang, Jeeyun Lee, Sang Joon Shin, Won Jin Chang, Eun-Ok Kim, Jason K SaSee the full list of authors
13 March 2024
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancerArun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi SatoSee the full list of authors
13 March 2024
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trialHeinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino, Mark Kochenderfer, Elena Elez, Spencer H Shao, Dustin Deming, Regan Holdridge, Timothy Larson, Eric Chen, Amit Mahipal, Antonio Ucar, Dana CullenSee the full list of authors
13 March 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaDanny Rischin, Brett G M Hughes, Nicole Basset-Séguin, Dirk Schadendorf, Samantha Bowyer, Sabiha Trabelsi Messai, Friedegund Meier, Thomas K Eigentler, Victoria Casado Echarren, Brian Stein, Marie Beylot-Barry, Sophie Dalac, Brigitte Dréno, Michael R Migden, Axel HauschildSee the full list of authors
11 March 2024
Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumorsQian Tao, Nian Liu, Jie Wu, Jing Chen, Xiang Chen, Cong Peng
11 March 2024
Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancerXin Xu, Zhiyong Sun, Qiang Liu, Yao Zhang, Lei Shen, Chenpeng Zhang, Haiping Lin, Bin Hu, Ling Rong, Haiyan Chen, Xiaohang Wang, Xiaojing Zhao, Yong-Rui Bai, Qing Ye, Xiumei Ma
7 March 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason J Luke, Ignacio Melero, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti SanyalSee the full list of authors
7 March 2024
Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysisKatsuhiko Nara, Satoru Taguchi, Sebastiano Buti, Taketo Kawai, Yukari Uemura, Takehito Yamamoto, Haruki Kume, Tappei Takada
7 March 2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromesAmin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame, Elias Bou Farhat, Dory Freeman, Edward El-Am, Arjun Ravishankar, Bachar Ahmad, Frank Aboubakar Nana, David Kaldas, Abdul Rafeh NaqashSee the full list of authors
5 March 2024